Opal Capital’s Relay Therapeutics RLAY Stock Holding History

Opal Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,401	Closed	-$98.6K	–	209
2025 Q4	$98.6K	Buy	+11,401	New	+$81.4K	0.02%	186

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Opal Capital's RLAY Position: Q1 2026 in Review

Opal Capital sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 11,401 shares — an estimated $98.6K sold.

Opal Capital first reported a position in RLAY in Q4 2025 and held it in 1 quarter. The position peaked at $98.6K in Q4 2025. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

Opal Capital reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
Opal Capital sold 11,401 Relay Therapeutics shares in Q1 2026, an estimated $98.6K.
Opal Capital first reported a position in Relay Therapeutics in Q4 2025 and held it in 1 quarter.
Opal Capital's Relay Therapeutics position peaked at $98.6K in Q4 2025.
244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.